Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.75 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.71 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.71 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.71 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28825919 | 0.86 | TGFBR1 (0.82) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL373558 | 0.86 | TGFBR1 (1.00) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL6181382 | 0.84 | TGFBR1 (0.78) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL5139175 | 0.83 | TGFBR1 (0.79) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| Sb-431542 SCHEMBL29359059 | 0.83 | TGFBR1 (1.00) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL2617116 | 0.83 | TGFBR1 (0.84) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| Sb-431542 SCHEMBL29381798 | 0.83 | TGFBR1 (1.00) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL6475046 | 0.83 | TGFBR1 (0.84) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| Sb-431542 SCHEMBL310028 | 0.83 | TGFBR1 (1.00) | TGFBR1ACVR1BMAPTALDH1A1HPGD | |
| SCHEMBL373248 | 0.83 | TGFBR1 (1.00) | TGFBR1ACVR1BMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | claimed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | claimed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | disclosed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | TGFBR1 56/4885ACVR1B 6/4885MAPT 3024/4885 |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | TGFBR1 157/4885ACVR1B 273/4885MAPT 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.